Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Chronic myelogenous leukemia

In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

Leukemia volume 34, pages 929–931 (2020)Cite this article

Subjects

Philadelphia-chromosome positive (Ph+), BCR-ABL1+ acute lymphoblastic leukemia (ALL) is a distinct entity that is characterized by specific genomic alterations, low sensitivity to chemotherapy, unstable responsiveness to tyrosine kinase inhibitors (TKIs), and a poor prognosis [1,2,3]. The frequency of Ph+ ALL varies with age, ranging from <10% in children to about 50% in the elderly [3, 4]. Ph+ ALL is driven by a reciprocal translocation between chromosome 9 and chromosome 22, leading to the formation of hybrid fusion genes, that are all leukemogenic but can vary depending on the site of the breakpoints [5, 6]. The most common gene, that accounts for about 70–80% of all cases, results from the fusion of BCR exon 1 on chromosome 22 with ABL1 exon 2 on chromosome 9, much more rarely with ABL1 exon 3. The resulting e1a2 (or e1a3) fusion gene codes for a leukemogenic protein of 185–190 kd (P190). In 20–30% of cases, the breakpoint on chromosome 22 is downstream to BCR exon 1, resulting from the fusion of ABL1 exon 2 on chromosome 9 with either BCR exon 13 or BCR exon 14 on chromosome 22. The resulting fusion transcripts are named e13a2 (also known as B2A2), and e14a2 (also known as B3A2), respectively. The fusion e13a2 can give rise to only one transcript (e13a2) and one leukemogenic protein of 210 kd (P210). The fusion e14a2 usually give rise to one transcript (e14a2) that is longer, and codes for a leukemogenic protein that is also called P210, but has 25 additional amino acids and different secondary structure elements [5, 6]. Sometimes the e14a2 fusion gene, that retains BCR exon 13, can also generate a minor amount of e13a2 transcript, because of alternative splicing mechanisms. Therefore, the BCR-ABL1P210+ leukemias have two different molecular signatures:e13a2, and e14a2 (+_e13a2). The frequency of the two signatures has never been systematically investigated. In a paper from the MD Anderson Cancer Center it was reported that of 17 patients with Ph+, BCR-ABL1P210+ 76% expressed e13a2 [7].

In a previous international study of the frequency of the two transcripts in 45,503 patients with newly diagnosed BCR-ABL1P210+ chronic myeloid leukemia (CML), it was found that 17,216 patients (37.9%) expressed only e13a2, with a proportion that varied with age, from 39.6% in children and adolescents down to 31.6% in the elderly, and with sex, from 36.5% in females up to 39.2% in males [8]. To assess the frequency of e13a2 in BCR-ABL1P210+ ALL, we collected the molecular data from 849 patients with Ph+, BCR-ABL1P210+ ALL, from 39 Institutions, as a first quick step of a project that was designed to evaluate the clinical and biological characteristics and the outcomes of BCR-ABL1+ ALL according to the different transcripts. Completing the project will take more time and more resources, and we report here the first data set: 497 patients (58.5%) expressed only e13a2, a proportion that was significantly higher than the proportion of e13a2 that was found in newly diagnosed chronic phase CML (37.9%) (Fisher’s exact test, two-sided, p value < 0.0001). This difference cannot be explained by age; indeed the frequency of Ph+ ALL increases with age and is highest in the elderly, where the frequency of e13a2 in CML is the lowest [3, 4, 8]. The finding that the distribution of the different breakpoints in BCR-ABL1 fusion gene is not by chance, being significantly different between CML and Ph+ ALL is of interest. While we are collecting data to compare the characteristics, the response to therapy and the outcomes according to transcript, other important questions, are unanswered. First, why is the distribution different, is the cause related to the cell where the translocation occurs (a multipotent stem cell versus a committed lymphoid progenitor)? Is it due to a different chromatine structure that may influence the position of the breakpoint and the formation of the hybrid gene [9], or to an aberrant activity of the machinery for V(D)J or class switch recombination, or to different DNA-repair mechanisms, or to a microenvironment with a different oxygen tension? Second, what are the biological and clinical consequences of the difference in transcript types, the e13a2 gene being possibly associated with a minor sensitivity to TKIs in CML [8], and at the same time being prevalent in an aggressive leukemia like ALL, that is only temporarily sensitive to TKIs [10,11,12]? Third, is the transcription efficacy of the two fusion genes identical, or is the turnover of the two mRNAs different, resulting in different amounts of transcript? Fourth, have the two proteins the same leukemogenic potency, have they the same turnover, is the cellular level identical? Fifth, is the sensitivity of the two chimeric proteins to TKIs different? Sixth, is the immunogenicity of the two chimeric transcripts and of the two resulting proteins identical? Of course all these questions need to be addressed also for the more common form of Ph+, BCR-ABL1P190+ ALL (e1a2 or e1a3) [13,14,15], not forgetting that P190 can also cause CML, although rarely [8]. The answer to these questions may help to optimize the management of Ph+ ALL patients, and also to improve our knowledge on the relationships of genes and gene/protein expression with leukemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.

    Article  CAS  Google Scholar 

  2. Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:1043. vi

    Article  Google Scholar 

  3. Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biologic features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98:1702–10.

    Article  CAS  Google Scholar 

  4. Burmeister T, Schwartz S, Bartram CR, Gokbuget N, Hoelzer D, Thiel S. Patients’ age and BCR-ABL frequency in adult B-cell precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918–9.

    Article  CAS  Google Scholar 

  5. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–84.

    Article  CAS  Google Scholar 

  6. Chereda B, Melo JV. The biology and pathogenesis of chronic myeloid leukemia. In: Hehlmann R, editor. Chronic myeloid leukemia. Switzerland: Springer International Publishing; 2016. p. 17–40.

    Chapter  Google Scholar 

  7. Ravandi F, O’Brien S, Cortes JE, Thomas DM, Garris R, Faderl S, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158–64.

    Article  CAS  Google Scholar 

  8. Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. an international overview. Leukemia. 2019. https://doi.org/10.1038/s41375-018-0341-4.

  9. Hai A, Kizilbash NA, Zaidi SH, Alruwaili J, Shahzad K. Differences in structural elements of Bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Bioinformation. 2014;10:108–14.

    Article  Google Scholar 

  10. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimomdo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–8.

    Article  CAS  Google Scholar 

  11. Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–8.

    Article  Google Scholar 

  12. Malagola M, Papayannidis C, Baccarani M. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. Ann Hematol. 2016;95:681–93.

    Article  CAS  Google Scholar 

  13. Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, Sobrinho-Simoes MA, et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia. 2010;24:1742–50.

    Article  CAS  Google Scholar 

  14. Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe D, et al. Differences in structural elements of bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Leukemia. 2017;31:1502–15.

    Article  CAS  Google Scholar 

  15. Cutler J, Tahir R, Sreenivasamurthy SK, Mitchell C, Renuse S, Nirujogi RS. Differential signaling through p190 and p210 BCR-ABL fusion proteins reveales by interactome and phosphoproteome analysis. Leukemia. 2017;31:1513–24.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the European Leukemia Net Foundation and by AIRC 5×1000 (21198). The technical assistance of Mrs Chiara Ferri is kindly acknowledged.

Author information

Authors and Affiliations

  1. Institute of Hematology “L. and A. Seràgnoli”, Bologna University, Bologna, Italy

    Michele Baccarani & Carolina Terragna

  2. Department of Pathology, St. Jude Children’s Cancer Research Hospital, Memphis, TN, USA

    Ilaria Iacobucci

  3. Heamatology, Department of Precision and Translational Medicine, Sapienza University, Rome, Italy

    Sabina Chiaretti & Robin Foà’

  4. Christian Medical College, Vellore, India

    Poonkuzhali Balasubramanian

  5. ECOG-ACRIN Leukemia Laboratory, Montefiore Medical Center, New York, NY, USA

    Elisabeth Paietta

  6. Hammersmith Hospital, London, UK

    Letizia Foroni

  7. MLL Munich, Leukemia Laboratory GmbH, Munich, Germany

    Sabine Jeromin

  8. Federico II University, Naples, Italy

    Barbara Izzo

  9. ASST Papa Giovanni XXIII, Bergamo, Italy

    Orietta Spinelli

  10. PGIMER, Chandigarh, India

    Neelam Varma

  11. Institut Pasteur, Tunis, Tunisie

    Samia Menif

  12. AIIMS, New Delhi, India

    Tulika Seth

  13. CHU Bordeaux-Haut Léveque, Bordeaux, France

    Audrey Bidet

  14. Fundeni Clinical Institute, Bucharest, Romania

    Daniel Coriu

  15. San Raffaele University, Milan, Italy

    Francesca Lunghi

  16. University Hospital and Masaryk University, Brno, Czech Republic

    Jiri Mayer

  17. AOU Careggi, Florence, Italy

    Barbara Scappini

  18. St. James Hospital, Dublin, Ireland

    Stephen Langabeer

  19. Universitat Leipzig, Leipzig, Germany

    Jacqueline Maier

  20. The Royal London Hospital, London, UK

    Emma Burt

  21. Udine University, Udine, Italy

    Anna Candoni

  22. Bari University, Bari, Italy

    Francesco Albano

  23. Modena and Reggio Emilia University, Modena, Italy

    Mario Luppi

  24. University Clinical Center, Ljubljana, Slovenia

    Irena Zupan

  25. Children’s Cancer Research Institute, Wien, Austria

    Thomas Lion

  26. University Hospital Center, Zagreb, Croatia

    Renata Zadro

  27. Catania University, Catania, Italy

    Francesco di Raimondo

  28. Islamic Azada University and Payvand Lab, Tehran, Iran

    Behzad Poopak

  29. Orbassano Hospital, Turin University, Turin, Italy

    Giovanna Rege-Cambrin

  30. Cardarelli Hospital, Naples, Italy

    Mario Annunziata

  31. Universidad Nacional de Asuncion, San Lorenzo, Paraguay

    Ana Ayala

  32. Instituto de Prevision Social, Asuncion, Paraguay

    Victor Salinas-Viedma

  33. Hospital Maciel, Montevideo, Uruguay

    Ana Ines Prado

  34. NHS-Grampian, Aberdeen, UK

    Benedict Milner

  35. Pisa University, Pisa, Italy

    Sara Galimberti

  36. Department of Hematology, VUMC, Amsterdam, The Netherlands

    Jeroen Janssen

  37. Infermi Hospital, Rimini, Italy

    Valentina Polli

  38. S.C. Hematology, Cuneo, Italy

    Lorenzo Comba

  39. Ancona University, Ancona, Italy

    Beatrice Borsellino

  40. Campus University, Rome, Italy

    Ombretta Annibali

  41. University Hospital, Parma, Italy

    Monica Crugnola

  42. Varese University, Varese, Italy

    Francesco Passamonti

Authors
  1. Michele Baccarani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilaria Iacobucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sabina Chiaretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robin Foà’
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Poonkuzhali Balasubramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elisabeth Paietta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Letizia Foroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sabine Jeromin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Barbara Izzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Orietta Spinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Neelam Varma
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Samia Menif
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Carolina Terragna
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Tulika Seth
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Audrey Bidet
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Daniel Coriu
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Francesca Lunghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Jiri Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Barbara Scappini
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Stephen Langabeer
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Jacqueline Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Emma Burt
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Anna Candoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Francesco Albano
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Mario Luppi
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Irena Zupan
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Thomas Lion
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Renata Zadro
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Francesco di Raimondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Behzad Poopak
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Giovanna Rege-Cambrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Mario Annunziata
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. Ana Ayala
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. Victor Salinas-Viedma
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. Ana Ines Prado
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. Benedict Milner
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. Sara Galimberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  38. Jeroen Janssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  39. Valentina Polli
    View author publications

    You can also search for this author in PubMed Google Scholar

  40. Lorenzo Comba
    View author publications

    You can also search for this author in PubMed Google Scholar

  41. Beatrice Borsellino
    View author publications

    You can also search for this author in PubMed Google Scholar

  42. Ombretta Annibali
    View author publications

    You can also search for this author in PubMed Google Scholar

  43. Monica Crugnola
    View author publications

    You can also search for this author in PubMed Google Scholar

  44. Francesco Passamonti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michele Baccarani.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baccarani, M., Iacobucci, I., Chiaretti, S. et al. In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. Leukemia 34, 929–931 (2020). https://doi.org/10.1038/s41375-019-0591-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0591-9

This article is cited by

Search

Advanced search

Quick links